Welcome to our dedicated page for Mannkind news (Ticker: MNKD), a resource for investors and traders seeking the latest updates and insights on Mannkind stock.
MannKind Corporation (MNKD) specializes in innovative inhaled therapies for diabetes and respiratory diseases, notably through its FDA-approved Afrezza® inhaled insulin. This page aggregates official announcements, clinical trial updates, and strategic partnership news critical for understanding the company's trajectory.
Investors and researchers will find curated press releases covering financial results, regulatory milestones, and technology licensing agreements. The collection emphasizes developments in MannKind's core platforms: the Technosphere® drug delivery system and iSPERSE™ formulation technology.
Content includes updates on pulmonary arterial hypertension treatments, diabetes management solutions, and global expansion initiatives. All materials maintain factual accuracy without speculative analysis, adhering to financial disclosure standards.
Bookmark this page for streamlined access to MNKD's latest business developments and scientific advancements. Verify time-sensitive details directly through company filings or official communications.
MannKind Corporation (MNKD) is partnering with NTT INDYCAR SERIES driver Conor Daly for a special event during the Chevrolet Detroit Grand Prix week. The event, scheduled for May 29, 2025, at Full-Throttle Adrenaline Park in Novi, MI, will feature Daly sharing his experience living with Type 1 diabetes and racing go-karts with local youth.
Daly, diagnosed with T1D at age 14, is the only known U.S. professional racing driver competing full-time with the condition. He will drive the No. 76 "Tired of Pricks?" Chevrolet for Juncos Hollinger Racing at the Detroit Grand Prix. His notable achievements include a career-best 6th place finish at the 2022 Indy 500, leading the most laps at the 2021 Indy 500, and becoming the first driver to compete in both NASCAR and IndyCar on consecutive Texas weekends in 2023.
MannKind Corporation (MNKD), a company specializing in inhaled therapeutic products for endocrine and orphan lung diseases, has announced its participation in two upcoming investor conferences. CEO Michael Castagna and CFO Chris Prentiss will present at:
- RBC Capital Markets 2025 Global Annual Healthcare Conference on Tuesday, May 20 at 8:00 a.m. ET
- Jefferies Global Healthcare Conference on Thursday, June 5 at 2:35 p.m. ET
Both conferences will be held in New York City. Live audio webcasts will be available on MannKind's investor relations website, with recordings accessible for approximately 90 days after the events.
MannKind Corporation (MNKD) has scheduled its Q1 2025 financial results announcement for May 8, 2025, before market open. The company will host a webcast at 9:00 a.m. Eastern Time featuring CEO Michael Castagna and CFO Chris Prentiss to discuss the quarterly results and provide a business update. The webcast will be available through MannKind's investor relations website, with a replay accessible for approximately 90 days following the call.
MannKind (MNKD) has announced a continued partnership with Juncos Hollinger Racing (JHR) driver Conor Daly for the 2025 NTT INDYCAR Series season. Daly, the only known U.S. pro racing driver competing full-time with type 1 diabetes, will showcase a striking 'Tired of Pricks?' livery at the Acura Grand Prix of Long Beach on April 13.
MannKind will serve as primary sponsor for the No. 76 Chevrolet at three major events: Long Beach Grand Prix, Detroit Grand Prix (June 1), and World Wide Technology Raceway (June 15). The company will maintain an associate sponsorship throughout the 2025 season. The partnership aims to raise awareness about diabetes and innovative treatment options through InhaleMyInsulin.com.
Daly's impressive racing career includes notable achievements such as his career-best 6th place finish at the 2022 Indy 500, leading the most laps at the 2021 Indy 500, and securing JHR's first IndyCar podium at Milwaukee in 2024.
MannKind (MNKD) will present five studies on inhaled insulin at the 18th International Conference on Advanced Technologies and Treatments for Diabetes in Amsterdam, March 19-22, 2025. The presentations will showcase data from the INHALE-1 pediatric and INHALE-3 adult studies of Afrezza®.
Key presentations include research on pulmonary inhaled insulin, pediatric applications, sustained benefits from the INHALE-3 extension study, post-prandial glucose excursion comparisons between youth and adults with Type 1 diabetes, and a comparison study of inhaled Technosphere insulin plus insulin degludec versus usual care in adults.
The company anticipates filing a supplemental New Drug Application (sNDA) for Afrezza in the pediatric population in 2025. MannKind will also host booth #40 in the exhibit hall for scientific exchange with their Clinical Education Team.
MannKind (MNKD) reported strong financial results for Q4 and full year 2024. The company achieved annual revenues of $286M, up 43% from 2023, with Q4 revenues of $77M (+31% YoY). Net income for 2024 reached $28M, with Q4 contributing $7M.
Key financial highlights include debt principal reduction of $236M, with remaining convertible debt of $36M, and year-end cash position of $203M. The company made significant clinical progress, including positive results from the INHALE-1 pediatric trial for Afrezza, advancement of MNKD-101 to Global Phase 3, and completion of MNKD-201 Phase 1.
Commercial developments include Afrezza's approval in India with expected shipments in Q4 2025, and the appointment of Dominic Marasco as President of the Endocrine Business Unit. The company maintains a strong growth trajectory with an annual run rate of $300M by year-end.
MannKind (MNKD) has announced it will release its 2024 fourth quarter and full year financial results after market close on Wednesday, February 26, 2025. The company will host a webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a business update.
The conference call will feature CEO Michael Castagna and CFO Chris Prentiss. Investors can access the webcast through MannKind's website, and a replay will be available for approximately 90 days following the call.
MannKind (Nasdaq: MNKD), specializing in inhaled therapeutic products for endocrine and orphan lung diseases, has announced its participation in three major investor conferences during Q1 2025. The company's leadership, including CEO Michael Castagna and CFO Chris Prentiss, will present at:
- Oppenheimer 35th Annual Healthcare Life Sciences Conference (virtual) - February 11, 11:20 a.m. ET
- Leerink Partners 2025 Global Healthcare Conference in Miami - March 11, 8:40 a.m. ET
- Barclays 27th Annual Global Healthcare Conference in Miami - March 12, 1:30 p.m. ET
Live audio webcasts will be accessible through MannKind's investor relations website, with recordings available for approximately 90 days post-conference.
FAQ
What is the current stock price of Mannkind (MNKD)?
What is the market cap of Mannkind (MNKD)?
